NYSE · LLY
Eli Lilly and Company
$1,409.90+$36.20 (+2.64%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.74% below the high.
Loading market information…
OTC · AONC · USD
Stock price, earnings
Quote as of Oct 30, 2026, 06:37 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
American Oncology Network, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.88% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow American Oncology Network, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
American Oncology Network, Inc. engages in the provision of community-based oncology management. The firm provides various services to patients, including laboratory services for routine and specialized testing, in-house professional and technical pathology services with pathology reports, in-house specialty pharmacy services with patient education, financial assistance, and 24/7 patient assistance, and care management support services, including nutrition guidance. The company was founded in 2018 and is headquartered in Fort Myers, FL.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,409.90+$36.20 (+2.64%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.74% below the high.
$273.58-$1.62 (-0.59%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.99% below the high.
$293.93+$3.14 (+1.08%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.64% below the high.
$149.37+$3.04 (+2.08%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.81% below the high.
$406.52-$4.39 (-1.07%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 11.94% below the high.
$693.65-$15.53 (-2.19%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.56% below the high.
$466.24+$5.51 (+1.2%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.98% below the high.
$6.50-$0.16 (-2.33%)
Starling Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.91% below the high.
